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Aminopeptidase N, or CD13, is a receptor for serologically related coronaviruses of humans, pigs, and cats. A mouse line transgenic for
the receptor of human coronavirus-229E (HCoV-229E) was created using human APN (hAPN) cDNA driven by a hAPN promoter. hAPN-
transgenic mice expressed hAPN mRNA in the kidney, small intestine, liver, and lung. hAPN protein was specifically expressed on epithelial
cells of the proximal convoluted renal tubules, bronchi, alveolar sacs, and intestinal villi. The hAPN expression pattern within transgenic
mouse tissues matched that of mouse APN and was similar in mice heterozygous or homozygous for the transgene. Primary embryonic cells
and bone marrow dendritic cells derived from hAPN-transgenic mice also expressed hAPN protein. Although hAPN-transgenic mice were
resistant to HCoV-229E in vivo, primary embryonic cells and bone marrow dendritic cells were infected in vitro. hAPN-transgenic mice are
valuable as a source of primary mouse cells expressing hAPN. This hAPN-transgenic line will also be used for crossbreeding experiments
with other knockout, immune deficient, or transgenic mice to identify factors, in addition to hAPN, that are required for HCoV-229E
infection.
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Several different coronaviruses (CoV), including HCoV-
229E, SARS-CoV, HCoV-OC43, HCoV-NL63 (McIntosh,
2005), and HKU1 (Woo et al., 2005), infect humans.
Serological studies suggest that the prototypical strains
HCoV-229E and HCoV-OC43 cause from 15% to 30% of
human upper respiratory infections or colds (Holmes, 2001).
Studies on the pathogenesis of HCoV-229E respiratory0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.02.023
T Corresponding author. Department of Microbiology, University of
Colorado Health Sciences Center at Fitzsimons, Mail Stop 8333, PO Box
6511, Aurora, CO 80045, USA. Fax: +1 303 724 4226.
E-mail address: Kathryn.Holmes@UCHSC.edu (K.V. Holmes).
1 Present address: Wadsworth Center for Laboratories and Research, New
York State Department of Health, Albany, NY 12201-2002, USA.infections were limited to intranasal inoculation of human
volunteers because there was no small animal model.
HCoV-229E infection leads to coryza, headache, cough,
fever, disruption of nasal epithelium, and it can occasionally
cause lower respiratory tract infection (Chilvers et al.,
2001). There is in vitro and in vivo evidence for infection of
cells of the central nervous system (CNS) by human
coronaviruses, although no neurological symptoms have
been associated with HCoV-229E infection (Arbour et al.,
2000).
A cell surface receptor that mediates entry of HCoV-
229E into cells is human aminopeptidase N (hAPN) (Yeager
et al., 1992). When the single-stranded positive-sense
genomic RNA of HCoV-229E is transfected into cells
derived from many species, productive virus replication
ensues and progeny virions are efficiently released (Thiel et05) 185–197
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tropism and species specificity of HCoV-229E. For exam-
ple, mouse fibroblasts that are nonpermissive for HCoV-
229E become susceptible after transfection with cDNA
encoding hAPN (Yeager et al., 1992). Porcine and feline
coronaviruses also use aminopeptidase N (APN) as their
cellular receptors (Delmas et al., 1992; Tresnan et al., 1996).
APN or CD13 is a 150–160 kDa type II glycoprotein that
is a metalloprotease (Noren et al., 1997). APN is expressed
as a dimer on the surface of epithelial cells of the kidney,
intestine, and respiratory tract. APN is also expressed by
granulocytes, fibroblasts, endothelial cells, cerebral peri-
cytes at the blood–brain barrier, synaptic membranes in the
central nervous system, as well as on antigen presenting
cells, such as macrophages and dendritic cells (Dong et al.,
2000; Noren et al., 1997; Riemann et al., 1999). The
biological activities of APN include the removal of
individual amino acids from amino-termini of small
peptides in the lumen of the small intestine, cleavage of
peptides bound to MHC class II molecules on antigen
presenting cells, angiogenic regulation, and degradation of
neurotransmitters at synaptic junctions (Bhagwat et al.,
2003; Noren et al., 1997; Riemann et al., 1999). Human
APN is also a marker for acute myeloid leukemia and plays
a role in tumor invasion (Riemann et al., 1999).
Several transgenic mouse models have proven useful for
studying viruses that normally infect humans. Therefore, we
developed mice transgenic for hAPN, and tested these
animals, or primary cells isolated from them, for suscept-
ibility to HCoV-229E. The hAPN transgene was designed to
be expressed in the epithelial cells of respiratory and
intestinal tracts where coronaviruses enter the host. The
human APN operon has two promoters separated by more
than 8 Kb and they direct the differential expression of
hAPN mRNA in various tissues (Shapiro et al., 1991). The
transgene was engineered to use the proximal human APN
promoter, active in epithelial cells of the intestine, lung,
liver, and kidney (Shapiro et al., 1991), to direct the
transcription of hAPN cDNA and the polyadenylation signal
from SV40 virus (Fig. 1). Eight lines of mice were produced
by pronuclear microinjection and hAPN expression was
analyzed. This study focuses on a single line of mice that
expressed the highest levels of hAPN mRNA and protein in
a variety of tissues. This hAPN transgenic line of mice, andFig. 1. Diagram of the hAPN operon and transgene cassette. The hAPN
cDNA was cloned downstream of the natural human APN epithelial
promoter and upstream of the 3VUTR of SV40 virus.cells derived from these animals, were tested for suscept-
ibility to HCoV-229E.Results
Mouse cells transfected with the hAPN transgene construct
were permissive to HCoV-229E and produced infectious
virus
The transgene construct and a plasmid that encodes a
neomycin resistance (Neo) gene driven by the SV40
promoter were co-transfected into mouse CMT93 cells to
show that hAPN protein was produced from the transgene
and that it functioned as a receptor for HCoV-229E. FACS
analysis with anti-hAPN MAb-WM15 showed that 29% of
the G418 resistant co-transfected cell population expressed
hAPN on the cell surface, whereas the control cells
transfected with Neo vector alone did not show any
reactivity to the anti hAPN MAb (data not shown). Control
cells and the hAPN co-transfected cells were inoculated
with HCoV-229E and the titer of released virus (Control-S
and hAPN-S) or the total cell associated plus released virus
(Control-T and hAPN-T) was determined at various times
post-inoculation by plaque assay (Fig. 2). The data show
that HCoV-229E entered, replicated, and infectious virus
was efficiently released from mouse cells expressing hAPN
protein (Fig. 2). The hAPN transgene construct/Neo co-
transfected cells were also sorted for hAPN expression by
FACS, and 88% were positive for cell surface expression
post-sort (data not shown). Transfected cells sorted by
hAPN expression were inoculated with a low MOI (0.001)
and the supernatants were harvested over 72 h (Fig. 2,
hAPN sorted, solid squares). These data show that HCoV-
229E completed multiple rounds of replication in mouse
cells that expressed hAPN. Cell lines were generated from
the hAPN-positive population and analyzed for reactivity
with a panel of anti-hAPN MAbs (WM15, WM47, MY7,
DW1, Y2K, and BB1) that bind to multiple epitopes
(Ashmun et al., 1995). MAb-DW1, -Y2K, and -BB1 are
new anti-hAPN receptor MAbs and inhibit virus infection.
FACS analysis of the hAPN-positive cell lines showed they
reacted similarly with all six of the anti-hAPN MAbs,
indicating proper surface conformation of hAPN on the
mouse CMT93 cells (data not shown).
hAPN mRNA was expressed in a tissue-specific manner by
the transgene construct
The proximal hAPN promoter used in the transgene was
expected to be very active in the epithelial cells of the
respiratory and enteric tracts and in the proximal convoluted
tubules of the kidney. Progeny mice from 8 founder animals
were initially screened by a hAPN-specific RT-PCR assay
designed to amplify only polyadenylated RNA from total
RNA isolated from the small intestine. One of these lines
Fig. 2. Mouse CMT93 cells transfected with the hAPN transgene construct
are productively infected by HCoV-229E. The hAPN transgene was co-
transfected with a neomycin-resistant plasmid (PCR 3.0) into a mouse
epithelial cell line (CMT93) and selected for G418 resistance. Control cells
were transfected with PCR 3.0 alone (open and solid circles), the other cells
were co-transfected with the hAPN transgene plasmid and PCR 3.0 (open
and solid diamonds). The cells were inoculated at an MOI of 0.6 with
HCoV-229E and the titer of virus released into the supernatant (solid circle
and diamond) and total virus produced (open circle and diamond) was
determined by plaque assay. hAPN-expressing cells were also sorted by
FACS (88% were hAPN-positive post-sort) and were inoculated with
HCoV-229E at an MOI of 0.001. The titer of virus released into the
supernatant from the sorted cells was determined over 72 h (solid squares).
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subsequent studies (data not shown). Total RNA was
isolated from the kidney (K), small intestine (SI), lung
(L), spleen (S), liver (Li), muscle (M), and heart (H) of non-
transgenic and hAPN-transgenic mice. The hAPN transcript
was identified by a 712-bp amplicon visible by ethidiumFig. 3. The hAPN-transgenic mice express hAPN mRNAwith a tissue-specific dis
lung (L), spleen (S), brain (B), liver (Li), muscle (M), and heart (H) of non-transg
used a forward primer specific for hAPN (hAPN-2880) and a tailed oligo dT rev
agarose gel electrophoresis and stained with ethidium bromide (RT). The expected
100-bp DNA ladder (Invitrogen), were run in the first and last lanes. Hemi-nested
using an internal hAPN forward primer and the same reverse primer used for t
specificity of the assay and produces a 439-bp DNA fragment when hAPN transbromide staining in the kidney, small intestine, and liver of
the transgenic mice and it was not amplified from the RNA
of the non-transgenic animal tissues (Fig. 3, RT). The hAPN
transcript amplicon was shown to be specific by Southern
blot using a 32P labeled RNA probe complementary to the 3V
terminus of hAPN and part of the SV40 3VUTR that is
specific to the transgene (data not shown). This assay
demonstrated that the 712-bp amplicons visible by ethidium
bromide staining and a band amplified from the lung RNA
of the hAPN-transgenic mouse were specific to hAPN
mRNA transcription (data not shown). The smaller ampli-
cons observed in the lung, brain, and liver of both the non-
transgenic and the hAPN-transgenic mice did not hybridize
with the hAPN-specific probe and therefore were non-
specific amplification products (data not shown). When the
sensitivity of hAPN mRNA detection was increased using
hemi-nested PCR that maintained the specificity for a
polyadenylated hAPN transcript, a 439-bp amplicon was
identified in every tissue tested in the transgenic mice (Fig.
3, HN). The data showed that hAPN mRNA was expressed
at qualitatively higher levels in the kidney, small intestine,
liver, and to a lesser extent in the lung, which was identified
by Southern blot. This expression pattern corresponded to
the tissue-specific expression pattern found in previous
transcriptional analysis of the proximal hAPN promoter
(Shapiro et al., 1991).
Human APN protein was expressed with the same cellular
distribution as mouse APN in the small intestine and the
kidney
To identify expression of hAPN and mouse APN
(mAPN) proteins in the small intestine and kidney oftribution. Total RNAwas isolated from the kidney (K), small intestine (Si),
enic and hAPN-transgenic mice. Amplicons from an RT-PCR reaction that
erse primer specific for the poly-A tail (oligodT/Xho1) were subjected to
size of the RT-PCR amplicons was 712 bp and molecular weight markers,
(HN) PCR of an aliquot of the hAPN RT-PCR reaction was also preformed
he RT-PCR reaction. This HN-PCR reaction increases the sensitivity and
gene mRNA is present.
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immunocytochemistry with a biotinylated MAb-DW1 or
a rat MAb-R3-242 against mAPN. These were detected
by either streptavidin-HRP or a biotinylated rabbit anti-rat
followed by streptavidin-HRP, respectively. The Vector
Red substrate used stained regions bound by antibodies
red and was also fluorescent. The sections were counter-
stained with hematoxylin. The data showed the cell type
distribution expected for mAPN in the epithelial cells of
the brush border along the villi of the small intestine and
by cells of the proximal convoluted tubule in the kidney
(Fig. 4, anti-mAPN). Both the non-transgenic and the
hAPN-transgenic mice showed similar mAPN protein
distribution patterns, demonstrating that expression of
the hAPN protein in the transgenic animals did not
dramatically influence the level of mAPN expressed.
Human APN protein was expressed in the small intestine
and kidney of the transgenic mice in the same manner as
mAPN (Fig. 4, anti-hAPN). The hAPN protein was
expressed on the brush border membrane by epithelial
cells on the intestinal villi and by cells in the proximal
convoluted tubules of the kidney (Fig. 4, anti-hAPN).
MAb-DW1 binding suggests that hAPN expressed in the
mouse tissues was in the proper conformation for
interaction with HCoV-229E.Fig. 4. Immunohistochemistry of cryosections shows that the hAPN has the same c
the small intestine or kidney of age matched non-transgenic and hAPN-transgenic m
242 or with a mouse anti-hAPN MAb-DW1 and stained using Vector RedR and co
and these images are shown in the panels below the hematoxylin counter-stainedThe hAPN protein was expressed similarly in homozygous
female, heterozygous female, and hemizygous male
transgenic mice
The hAPN expression corresponded with a transgene
cassette that was inserted into the X chromosome of this
transgenic line. The APN expression in the various
genotypes was determined using cryosections of the small
intestine from non-transgenic (XX, XY) and hAPN homo-
zygous (XhXh), heterozygous (XhX), and hemizygous
(XhY) transgenic mice. The same expression pattern of
both hAPN and mAPN proteins was detected in the brush
border membrane of the small intestine (Fig. 5A). Fluo-
rescent Vector red staining of mAPN was observed in all
mice, and hAPN protein was detected only in transgenic
mice (Fig. 5A).
Epithelial cells of the secondary bronchi and alveolar sacs
in the hAPN-transgenic mice expressed hAPN that
corresponded with mouse APN expression
We were particularly interested in the localization of
hAPN in respiratory tissues of the hAPN-transgenic mice,
because HCoV-229E is a respiratory pathogen. Our goal
was to express hAPN on the epithelial cells of theellular distribution as mouse APN in transgenic animals. Serial sections from
ice were tested for reactivity with a rat anti mouse APN (mAPN) MAb-R3-
unter stained with hematoxylin. The Vector Red substrate is also fluorescent
images.
Fig. 5. Homozygous, heterozygous, and hemizygous hAPN-transgenic
mice all express hAPN with a similar expression pattern and hAPN was
expressed on the epithelial surface of the lungs. (A) Serial cryosections of
small intestine from age matched non-transgenic females (XX), hetero-
zygous females (XhX), homozygous females (XhXh), non-transgenic males
(XY), and hemizygous males (XhY) were analyzed for expression of mouse
APN (mAPN) using rat MAb-R3-242 to mAPN or with a mouse anti-hAPN
MAb-DW1 and binding was determined by a fluorescent substrate (Vector
RedR). (B) Cryosections of lungs from age matched non-transgenic and
homozygous hAPN-transgenic mice were analyzed with a MAb-R3-242
specific to mouse APN (mAPN) or a MAb-DW1 against hAPN. Binding of
the MAbs was revealed by a fluorescent substrate (Vector RedR).
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Cryosections of lungs from non-transgenic and homozygous
hAPN-transgenic mice stained with anti-mAPN-R3-242 or
with anti-hAPN-DW1 were used to analyze expression of
mAPN or hAPN proteins, respectively. Mouse APN was
detected in the secondary bronchi and alveolar sacs of both
the non-transgenic and hAPN-transgenic mice (Fig. 5B). In
transgenic animals, hAPN protein was expressed with the
same distribution pattern as mAPN (Fig. 5B). The data show
that the proximal human APN promoter directed expression
of hAPN protein in the respiratory tract of transgenic mice
with the appropriate cell-specific distribution.
HCoV-229E infection of the hAPN-transgenic mice was not
detected after intranasal, intracranial, or intragastric
inoculation
Many trials were conducted to determine if adult trans-
genic animals were susceptible to HCoV-229E after intra-
nasal inoculation, the natural route of infection. Mice of a
variety of ages (10 days, 3 weeks, 3 months, and 1.5–2
years) were tested and evidence of infection of the hAPN-
transgenic animals was for the most part negative. Anes-
thetized mice were inoculated with 1  107 to 1  108 PFU
of HCoV-229E and examined for evidence of virus
replication by clinical signs, gross pathology, virus titration,
and sensitive RT-PCR assays specific for HCoV-229E. No
clinical signs or gross pathology were observed in either the
hAPN-transgenic or non-transgenic animals post inoculation
(pi). In some trials, the titer of infectious virus in respiratory
washes from hAPN-transgenic and non-transgenic mice was
determined. This showed that the titers of both hAPN-
transgenic and non-transgenic mice were very low (101–102
PFU/ml) 1 day pi and were below the limit of detection by 3
days pi (data not shown).
Very sensitive analysis of HCoV-229E genomic RNA
(gRNA) was done using RT-PCR specific for the nucleocap-
sid gene, or multiplex RT-PCR specific for the spike and
polymerase genes followed by nested PCR of the amplicons.
The nested PCR procedure consistently identified gRNA,
presumably from the input virus, in the RNA from the lungs
of both hAPN-transgenic and non-transgenic mice (data not
shown). To differentiate input virus gRNA from low level
HCoV-229E replication, we used RT-PCR to detect leader-
body junction containing subgenomic RNA (sgRNA) enco-
ding the N gene. The results showed that the RNA from the
lungs and/or nasal turbinates of HCoV-229E-inoculated mice
that were positive for gRNA consistently tested negative for
sgRNA that is produced during viral replication (data not
shown). However, one hAPN-transgenic animal tested
positive for N sgRNA in the lung (data not shown).
There is evidence of CNS infection by HCoV-229E in
humans, so we inoculated 2-day-old hAPN-transgenic and
non-transgenic littermates intracranially (Arbour et al.,
2000). The mice were tested for hAPN mRNA and HCoV-
229E sgRNA specific to virus entry and initiation of
Fig. 6. Some embryonic cells from the hAPN-transgenic mice express
hAPN protein and are infected by HCoV-229E. (A) Cells derived from non-
transgenic and hAPN-transgenic embryos were inoculated with HCoV-
229E at an MOI of 1 and fixed 20 h post-inoculation. Cells were tested for
hAPN expression (red) with a mouse anti-hAPN MAb-DW1 and for
expression of HCoV-229E proteins (green) with polyclonal goat antisera to
HCoV-229E. In addition, the overlay of these two images is shown
(merged). (B) Embryonic cells from non-transgenic and hAPN-transgenic
mice were inoculated with HCoV-229E at an MOI of 1, unbound virus was
removed by washing, and the titer of the virus in the supernatant at 4 h and
24 h post-infection was determined by TCID50 in MRC5 cells.
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detectable (data not shown) by the RT-PCR, hemi-nested
PCR procedure that detects hAPN transcripts in the brains of
adult mice (Fig. 3), and HCoV-229E sgRNA production was
not detected (data not shown). The data suggest that the
expression of the hAPN transgene correlated with the natural
expression of hAPN on synaptic junctions, which increases
with age, and infection of CNS of the hAPN-transgenic mice
needs to be examined further using older animals.
Transmissible gastroenteritis virus and porcine respira-
tory coronaviruses are genetically related to HCoV-229E
and use porcine APN as a cellular receptor (Delmas et al.,
1992). Hence, HCoV-229E has the potential to infect
epithelial cells in the intestine of hAPN-transgenic mice,
which expressed hAPN mRNA and protein (Figs. 3 and 4).
However, no evidence of HCoV-229E enteric infection was
observed after intragastric inoculation of adult hAPN-
transgenic and non-transgenic mice (data not shown). This
may be due to the fact that the spike glycoprotein of HCoV-
229E has a deletion when it is compared to the TGEV spike
glycoprotein. The HCoV-229E spike glycoprotein deletion
is similar to a deletion in the spike glycoprotein of some
porcine respiratory coronaviruses that only infect the
respiratory tract (Enjuanes et al., 1993).
Primary cells isolated from transgenic mouse embryos were
infected by HCoV-229E and produced infectious virus
Cell lines from embryos derived from hAPN-transgenic
and non-transgenic mice were established to determine if
hAPN protein expressed by the hAPN-transgenic mice was
a functional receptor for HCoV-229E. Human APN
expression on cells of the embryonic cultures was analyzed
by flow cytometry, and 3% of the cells derived from the
hAPN-transgenic mouse expressed the HCoV-229E receptor
within a range typically observed on human MRC5 cells,
while hAPN expression was not detected on cells derived
from non-transgenic mice (data not shown). Cells from the
non-transgenic and hAPN-transgenic mice were grown on
glass cover slips and inoculated with HCoV-229E at an MOI
of 1. Twenty hours post-inoculation, the cells were fixed and
expression of human APN or HCoV-229E proteins was
detected by immunofluorescence assay (IFA) using anti-
hAPN MAb-DW1 or polyclonal goat anti-HCoV-229E. The
cells derived from hAPN-transgenic embryos that expressed
hAPN protein were infected by HCoV-229E (Fig. 6A).
Embryonic cells derived from non-transgenic mice and
hAPN-transgenic mice, or human lung fibroblasts (MRC5),
were inoculated at an MOI of 1, and the virus in the
supernatant was quantified by TCID50 4 h and 24 h post-
inoculation. The HCoV-229E titer decreased below the limit
of detection in the non-transgenic embryo cells by 24 h post-
inoculation (Fig. 6B). In contrast, the titer of HCoV-229E in
the supernatant from hAPN-transgenic embryo cells
increased to 1  103 TCID50/ml by 24 h post-inoculation
(Fig. 6B). Only the cells derived from hAPN-transgenic
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229E, and this hAPN-positive population (3%) efficiently
produced infectious virus.
Dendritic cells derived from the bone marrow of the
hAPN-transgenic mice expressed hAPN and were
susceptible to HCoV-229E infection
Dendritic cells (DCs) are potent antigen presenting cells
that can present peptides in the context of both MHC class I
and class II molecules. In addition, both mouse and human
DCs are known to express APN (CD13) (Dong et al., 2000;
Summers et al., 2001; Woodhead et al., 2000). To determine
if dendritic cells of the hAPN-transgenic mice expressed
hAPN protein and were susceptible to HCoV-229E, we
derived DCs from the bone marrow (BM) of non-transgenic
and hAPN-transgenic mice. The BM–DCs were prepared by
isolating the BM from male littermates using magnetic
separation to remove T cell, B cell, and macrophage
precursors, and then culturing the remaining cells in medium
containing IL4 and GMCSF for 5–7 days (Turner et al.,
2004). Comparison of the fluorescence between BM–DCs
treated with no primary antibody (gray line) or a hamster
MAb to an irrelevant antigen (dotted line) by FACS showed
there was little non-specific reactivity (Fig. 7A, a and b). The
BM–DCs isolated from non-transgenic and hAPN-trans-
genic mice reacted similarly with a hamster MAb against the
DC marker CD11c (Fig. 7A, a and b, solid line with shaded
area under the curve). Fig. 7A, panels c and d, shows that the
BM–DCs from non-transgenic and hAPN-transgenic mice
reacted similarly with rat anti-mAPN MAb-R3-242 (solid
line shaded under the curve) when compared to cells treated
with no primary antibody (gray line) or nonspecific control
antibody (dotted line). MHC I (dashed line) and CEA-
CAM1a (not shown) also showed very similar levels of
expression in DCs derived from both the non-transgenic and
transgenic littermates (Fig. 7A, e and f). Thus, the cells
isolated and cultured from both hAPN-transgenic and non-
transgenic mice showed consistent expression of multipleFig. 7. Dendritic cells derived from the bone marrow of hAPN-transgenic
mice express hAPN and are infected by HCoV-229E. (A) Dendritic cells
were isolated from non-transgenic (a, c, and e) and hAPN-transgenic (b, d,
and f) male littermates and analyzed by cytofluorometry. The controls were
cells that were not treated with primary antibody (gray line) or treated with
antibodies (hamster, rat, or mouse) to an irrelevant antigen (dotted line).
The surface expression of CD11c (a and b, solid line with gray shading),
mouse APN (c and d, solid line with gray shading), MHC class I (e and f,
dashed line), and human APN (e and f, solid line with gray shading) were
identified with hamster MAb-HL3, rat MAb-R3-242, mouse MAb-KH117,
and MAb-DW1, respectively. Dendritic cells isolated from non-transgenic
and hAPN-transgenic mice were mock inoculated (M) or inoculated (I) with
HCoV-229E at an MOI of 1.0 at 4 8C. Unbound virus was removed by
washing and cells were incubated at 34 8C for 20 h. (B) Immunoblot
analysis of protein lysates was performed using polyclonal goat anti-HCoV-
229E that reacts strongly with nucleocapsid protein (arrow). (C) IFA of
acetone fixed hAPN-transgenic dendritic cells was done using anti-hAPN
MAb-DW1 (red) and with polyclonal goat anti-HCoV-229E (green).surface antigens. In contrast to the non-transgenic mice,
substantial hAPN expression (solid line with shading under
the curve) was observed on BM–DCs isolated from the
hAPN-transgenic mice, indicating that the DC-enriched
population of cells expressed the hAPN protein from the
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different anti-hAPN MAbs (DW1, Y2K, and WM47) that
bind to different regions of hAPN showed very similar
reactivity with BM–DCs from the hAPN-transgenic animals
and very little reactivity with BM–DCs from the non-
transgenic mice (data not shown). This indicates that the
hAPN on the DC surface was folded correctly and expressed
several epitopes important in HCoV-229E receptor activity,
as receptor binding MAb-DW1 andMAb-Y2K block HCoV-
229E infection (data not shown).
To test their susceptibility to HCoV-229E, the same BM–
DCs analyzed in Fig. 7A were inoculated with HCoV-229E
at an MOI of 1 or were mock inoculated. Analysis of the
supernatant media collected from the BM–DCs at 2 h and
20 h pi showed a two log10 increase in HCoV-229E titer
from the transgenic mice (data not shown). Whereas, a
decrease in virus titer was observed in the supernatant media
of BM–DC derived from the non-transgenic mice (data not
shown). Immunoblot analysis of proteins isolated from
mock (M) or HCoV-229E inoculated (I) cells showed that
BM–DCs from hAPN-transgenic mice were susceptible to
HCoV-229E as indicated by the doublet at ~45 kDa
characteristic of viral nucleocapsid (N) protein (Fig. 7B,
arrow). No viral antigens were detected in BM–DCs derived
from the non-transgenic mice. IFA showed expression of
hAPN protein (red) in most of the BM–DCs and infection of
some of the BM–DCs (green) from the hAPN-transgenic
mice (Fig. 7C). Thus, hAPN expression on the BM–DCs of
transgenic mice permitted infection by HCoV-229E and
resulted in the replication and release of virus in vitro.Discussion
The goals of this study were to develop hAPN-transgenic
mice that express hAPN protein in epithelial tissues in the
hopes that the animals would prove to be beneficial for the
study of HCoV-229E infection in vivo or that the response
of specific cell types to HCoV-229E could be studied in
vitro. APN has numerous biological activities, and many of
these depend on its enzymatic activity and tissue local-
ization. For example, APN plays important roles in
digestion, cancer, angiogenesis, synaptic activity, and is
responsible for cleaving peptides bound to MHC molecules
of antigen presenting cells (Bhagwat et al., 2003; Ishii et al.,
2001; Noren et al., 1997; Riemann et al., 1999). Thus,
hAPN-transgenic mice may prove valuable for many areas
of research in addition to HCoV-229E–host interactions.
The hAPN-transgene construct directed expression of
hAPN mRNA and protein in vitro when it was transfected
into CMT93 cells, which are derived from mouse intestinal
epithelium. The hAPN protein expressed by CMT93 cells
was recognized by a panel of six anti-hAPN MAbs that
recognize different epitopes of hAPN and also had
enzymatic activity. HCoV-229E inoculation of CMT93 cells
expressing hAPN protein produced considerable titers (4.5–5 log10) of HCoV-229E through multiple replication cycles
over 3 days. Therefore, hAPN protein expressed from the
transgene construct was transported to the surface of mouse
cells with normal epitopes, enzymatic activity, and in the
proper conformation for productive HCoV-229E replication.
In vivo hAPN mRNA and protein were detected in the
lung, small intestine, and kidneys, which corresponded with
expression of wild-type mAPN. The anti-hAPN MAb-DW1
used to specifically identify hAPN blocks virus infection.
Consequently, the region of hAPN that HCoV-229E
recognizes is probably in the proper conformation for virus
binding and entry in vivo as well as in vitro. The hAPN
transgene that expressed mRNA and protein was inserted in
the X chromosome and similar levels of hAPN protein were
expressed in tissues of hemizygous male as well as
heterozygous and homozygous female mice.
In vitro experiments with primary embryo cells and BM–
DCs derived from hAPN-transgenic mice showed that the
hAPN expressed on the cell surface by the transgene was a
functional receptor for HCoV-229E. Although a small
percentage of the hAPN-transgenic mouse embryo cell
population expressed hAPN, these positive cells were
susceptible to HCoV-229E infection and efficiently pro-
duced infectious virus. Therefore, cells isolated from hAPN-
transgenic mice were productively infected by HCoV-229E.
Dendritic cells (DCs) are extremely important antigen
presenting cells that are critical to the initiation of both the
adaptive and innate immune response of the host, and it is
clear that their interactions with pathogens can have both
positive and negative effects on pathogenesis (Liu, 2001;
Mellman and Steinman, 2001). Coronaviruses gain entry
into the host via respiratory or intestinal epithelium where
there are numerous DCs. APN/CD13 is expressed by
specific DC subsets and is important in maturation of
DCs, extracellular degradation of antigens, and may be
involved in T-cell activation (Amoscato et al., 1998; Liu,
2001; Summers et al., 2001; Woodhead et al., 2000).
Consequently, we studied mAPN and hAPN expression on
dendritic cells derived from the bone marrow (BM–DCs) of
non-transgenic and hAPN-transgenic mice. Expressions of
surface proteins including MHC I, CEACAM1a, mouse
APN, and CD11c were very similar in both the non-
transgenic and the hAPN-transgenic mice. In contrast,
hAPN was only expressed by the DC-enriched population
derived from the hAPN-transgenic mice. BM–DCs isolated
from the hAPN-transgenic mice were susceptible to HCoV-
229E, whereas BM–DCs derived from non-transgenic mice
were not. Our data demonstrate that DCs from hAPN-
transgenic mice are infected by HCoV-229E in a receptor-
dependent fashion, and Thiel et al. have shown that HCoV-
229E virus-like particles transduce human DCs (Thiel et al.,
2003). Therefore, DCs in the human respiratory epithelium
may play a role in the initiation of HCoV-229E infection
and its dissemination to other tissues. Other group 1
coronaviruses that infect cats and pigs may also infect
DCs via their cognate APN receptors (Delmas et al., 1992;
D.E. Wentworth et al. / Virology 335 (2005) 185–197 193Tresnan et al., 1996). Mouse DCs are also infected by
mouse hepatitis virus-A59, a group 2 coronavirus, in a
CEACAM1a receptor-dependent manner (Turner et al.,
2004). DC–coronavirus interaction may be a common
evolutionary mechanism of entry, dissemination, immuno-
modulation, and pathogenesis observed in diverse corona-
viruses, including feline infectious peritonitis virus, mouse
hepatitis virus, severe acute respiratory syndrome corona-
virus, and HCoV-229E (Ding et al., 2004; Holmes, 2001;
Jeffers et al., 2004; Konikova et al., 1998; Thiel et al., 2003;
Turner et al., 2004; Yang et al., 2004). In other viruses, such
as LCMV and measles, infection of DCs leads to severe
immunomodulation, impairment of antigen presentation,
and cytokine expression (Borrow et al., 1995; Hahm et al.,
2004; Naniche and Oldstone, 2000). The hAPN-transgenic
mice developed in this study will provide an excellent
reproducible source of hAPN-expressing mouse DCs to
study the effect HCoV-229E infection has on DC function.
Although the hAPN transgene was expressed in respira-
tory epithelial cells that are the principle targets of HCoV-
229E infection, our attempts to infect the hAPN-transgenic
mice with HCoV-229E by intranasal inoculation were
unsuccessful. HCoV-229E did not cause any clinical signs
of disease such as lethargy, weight loss, ruffled fur, or
rhinorrhea in the mice; however, many coronavirus infec-
tions are subclinical (Holmes, 2001). There was no increase
in virus titer in respiratory washes from hAPN-transgenic
mice compared to non-transgenic controls. The RT-PCR/
hemi-nested PCR procedure utilized to identify genomic
RNAwas more sensitive than plaque assay and could detect
as little as 1  105 PFU in vitro. We consistently observed
that the lung RNA from both non-transgenic and hAPN-
transgenic mice inoculated with HCoV-229E contained viral
gRNA, most likely from the inoculum. When lung samples
were tested for expression of sgRNAs that are produced
during replication of HCoV-229E, all but one mouse were
negative. Preliminary studies using other routes of inocu-
lation showed no evidence of HCoV-229E infection.
Other initial attempts to generate small animal models by
producing transgenic mice or rats that express specific viral
receptors have also had limited success (Blixenkrone-Moller
et al., 1998; Horvat et al., 1996; Hughes et al., 2003;
Niewiesk et al., 1997; Ren et al., 1990; Thorley et al., 1997;
Zhang and Racaniello, 1997). Subsequent modification of
the transgene constructs, inoculation strategies/routes, cross-
breeding with alpha/beta interferon-defective mice, identi-
fication of new receptors, and virus strain variation
improved models for measles virus and poliovirus (Crotty
et al., 2002; Hahm et al., 2004; Mrkic et al., 1998; Nagata et
al., 2004; Oldstone et al., 1999; Rall et al., 1997; Tatsuo and
Yanagi, 2002).
The reason(s) that cells from hAPN-transgenic mice were
susceptible to HCoV-229E in vitro but hAPN-transgenic
mice were not permissive to HCoV-229E infection remains
to be identified. Many factors that can be eliminated or
controlled in in vitro experiments cannot be controlled invivo. These include adsorption time, temperature, concen-
tration of virus at the cell surface, innate immune response,
and presence of non-specific inhibitors such as mucins or
pH. Some of these problems will be overcome by crossing
these hAPN-transgenic mice with knockout mice (e.g.,
CD13, STAT1) or other mouse lines. Identification of new
species-specific molecules that aid HCoV-229E binding or
entry will aid in the development of a better transgenic
mouse model. Angiotensin converting enzyme 2 (Ace2) is a
functional receptor for SARS-CoV, and like APN it is a
surface metalloprotease that is expressed in the respiratory
tract, small intestine, spleen, brain, liver, and kidney
(Hamming et al., 2004; Li et al., 2003; Wang et al.,
2004). DC-SIGN binds SARS-CoV spike glycoprotein
(Marzi et al., 2004; Yang et al., 2004) and we have shown
that CD209L can act as an alternative receptor for SARS-
CoV (Jeffers et al., 2004). CD209L, DC-SIGN, or other
species-specific receptors may also facilitate entry of HCoV-
229E and their identification will provide new tools to
improve hAPN-transgenic mice as a small animal model.
Factors specific to HCoV-229E could also produce the
results observed with the hAPN-transgenic mice. HCoV-
229E was isolated by serial blind passage in human em-
bryonic kidney cells in 1966 (Hamre et al., 1967; Holmes,
2001). Serial passage may have resulted in the accumulation
of mutations that are advantageous in vitro, but these
mutations could have adverse affects in vivo. New genomic
sequence information from HCoV-229E-related viruses that
are currently circulating may identify differences between
natural isolates and the laboratory adapted HCoV-229E
strain. Reverse genetics of HCoV-229E will allow the
correction of these mutations and allow the generation of
viruses that identify determinants critical to infection/patho-
genesis in hAPN-transgenic mice (Thiel et al., 2001).
The natural cellular distribution of the transgene product
is critical to the development of transgenic mice as models
to study pathogenesis. We demonstrated the tissue-specific
expression of hAPN mRNA and found that hAPN protein
distribution within these tissues corresponded with natural
mAPN expression. Our results show the value of the present
hAPN-transgenic line as a source of different primary cell
types for the elucidation of factors critical to virus entry and
the host response to HCoV-229E. For example, hAPN-
transgenic mouse BM–DCs can be used to gain a better
understanding of DC–coronavirus interactions. A similar
approach has proven very helpful for study of the interaction
of wild-type measles virus with DCs isolated from CD150-
transgenic mice (Hahm et al., 2004). These hAPN-trans-
genic mice may also be useful as models for new
coronaviruses or other human pathogens that may interact
with hAPN (Gredmark et al., 2004; Larsson et al., 1998;
Moller et al., 1999; van der Hoek et al., 2004). Cross-
breeding the present FVB/NJ hAPN-transgenic mouse line
with other mouse strains, knockout, or transgenic mice will
aid in the discovery of host mechanisms critical to
coronavirus resistance.
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Cells and viruses
Cells were maintained in appropriate medium supple-
mented with 2% Antibiotic-Antimycotic (GIBCO BRL,
Grand Island, NY) at 37 8C and 5% CO2 in Falcon tissue
culture-treated flasks or plates (Becton Dickinson and
Company, Franklin Lakes, NJ). Human diploid lung
fibroblasts, MRC5 cells (American Type Culture Collection
(ATCC), Rockville, MD), were grown from passage 19 to
27 in Eagle’s minimal essential medium (MEM) supple-
mented with 10% heat-inactivated fetal bovine serum
(FBS), 1 mM sodium pyruvate, and 1 mM non-essential
amino acids (GIBCO BRL). CMT93 cells (ATCC, Rock-
ville, MD) were grown in Dulbecco’s modified Eagle’s
minimal essential medium (DMEM) supplemented with
10% heat-inactivated FBS (GIBCO BRL). Embryonic cell
lines were established from pregnant non-transgenic and
homozygous hAPN-transgenic females on the 14th day of
pregnancy (Spector et al., 1998).
The prototypical strain, HCoV-229E, used in this study
was isolated from a patient with an upper respiratory
infection in 1966 (Hamre et al., 1967). This virus was
isolated by serial blind passage in human embryonic kidney
cells, and it can now be propagated in human lung
fibroblasts (Hamre et al., 1967). HCoV-229E was obtained
from ATCC (VR740) and a variant that was previously
adapted to growth at 37 8C (RW) was propagated in MRC5
cells at 37 8C and was used for the majority of the in vivo
experiments. HCoV-229E (DW6-W) was originally
obtained from ATCC and was propagated in MRC5 cells
at 34 8C (Wentworth and Holmes, 2001).
hAPN transgene construction and testing
The hAPN expression plasmid was produced by sub-
cloning an hAPN cDNA fragment (BamHII–BglII, partial
digestion), GenBank accession number M22324, from
pBSSK+ (Stratagene, La Jolla CA) into the pGem11
plasmid (Promega CO, Madison, WI) that contained a
1789-bp fragment of the proximal promoter of hAPN from
SacI to BamHI (the BamH1 site is within the coding
sequence of hAPN). Part of the 3V UTR of hAPN was
replaced with the 3VUTR and poly A signal from SV40
virus by ligating a BamHI–XbaI fragment from pRep4
(Invitrogen) into the hAPN plasmid previously digested
with BglII and XbaI. This created the transgene plasmid
pGem.APN.ds that could be linearized with SacI and XbaI
to yield the complete transgene (Fig. 1).
Mouse CMT93 cells at 50% confluency in 100-mm
dishes were transfected with 27 Ag of pCR3.0 (Invitrogen,
Carlsbad, CA) alone or were co-transfected with 5 Ag of
pCR3.0 and 22 Ag of pGem.APN.ds and 45 Al of pFX2
(Invitrogen) in 1.5 ml of Optimem (Invitrogen). Two days
post-transfection, the medium was replaced with mediacontaining 600 Ag/ml G418 (Invitrogen) and cells resistant
to G418 were selected. These stably transfected cells were
used for FACS analysis and HCoV-229E infection experi-
ments as a mixed population. This mixed cell population
was also sorted for hAPN expression using MAb WM15 as
previously described (Wentworth and Holmes, 2001). To
test the mixed population for receptor activity, HCoV-229E
was inoculated onto replicate wells of the control cells or the
hAPN transgene-transfected cells at an MOI of 0.6 in 0.3 ml
for 1 h at 34 8C and 5% CO2. The inoculum was removed
and the cells were washed 2 times with 2 ml of medium, and
3 ml of medium was added. The cells were incubated at
34 8C and 5% CO2, at 4 h, 24 h, 48 h, and 72 h post-
inoculation, the supernatants were collected, or the cells in
duplicate plates were scraped and pooled with the super-
natants for virus titration. The pooled cells and supernatants
were frozen and thawed 3 times, and cell debris removed by
centrifugation. Virus titration was determined by plaque
assay in MRC5 cells.
Transgenic mouse production and maintenance
The hAPN transgene cassette was microinjected into the
pronucleus of oocytes from FVB/NJ mice (Jackson labo-
ratories, Bar Harbor, MA). Fertilized ova bearing the new
hAPN transgene cassette were introduced into the uteri of
pseudopregnant FVB/NJ mice by microsurgery at the
University of Colorado Health Sciences Center Transgenic
Core Mouse Laboratory. DNA isolated from 8 founder lines
of mice was analyzed by PCR using intron-spanning
primers (DT-21 and DT-22) specific for hAPN cDNA.
APN has many biological functions and is involved in a
variety of cancers; however, we did not observe any
consistent abnormalities such as tumors, developmental
problems, or other obvious disease due to the expression of
hAPN in transgenic mice. Mice were humanely euthanized
consistent with the recommendations of the Panel on
Euthanasia of the American Veterinary Medical Association.
All work on mice was done under a protocol approved by
the Institutional Animal Care and Use Committee. The
animal facilities were supervised by veterinarians specializ-
ing in lab animal medicine, and the facility is operated under
the NIH Guide for the Care and Use of Laboratory Animals.
Antibodies, fluorescence activated cell sorting (FACS), and
immunofluorescence assay
Three new anti-hAPN MAbs (Y2K, BB1, and DW1) that
block HCoV-229E infection were generated by inoculating
Swiss Webster mice with NIH 3T3 cells expressing hAPN
(Zip cells) (Yeager et al., 1992) and screening the super-
natants of individual clones for the ability to block HCoV-
229E infection of MRC5 cells. The hybridomas were cloned
by limiting dilution and expanded to produce the MAbs.
MAb-Y2K blocked virus infection, but had no effect on the
enzymatic activity of hAPN. MAb-DW1 and MAb-BB1
Table 1
Oligonucleotides used for PCR
Forward primer Sequence (5V–3V) Reverse primer Sequence (5V–3V)
DT-021 CCCACTTCCAGAAGACCCC DT-022 AGTTCTCCCGGTAGGTCACC
DT-031 AGCCCACGTTCTCTCTGCC OligodT-Xhol TCCTCGAGGTTTTTTTTTTTTTTTTV
Leader-1 ACTTAAGTACCTTATCTATCTACA N-359R CCGTTTGCCCTTTCTAGTTCT
HAPN-2880 GTTCAAGAAGGACAACGAGGAA N-520R TCTGGTTCTGAATTCTTGCGC
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activity by approximately 55% (data not shown). MAb
DW1 was purified, biotinylated, and used to stain the
transgenic mouse tissues. Other anti-hAPN MAbs, WM47
(DAKO Corporation, Carpinteria, CA), MY7 (BioGenex,
San Ramon, CA), and WM15 (Biodesign, Kennebunk, ME)
were purchased. Control MAb against cholera toxin was
kindly provided by Dr. Randall Holmes (University of
Colorado Health Sciences Center, Denver, CO). Rat anti-
mouse APN MAb-R3-242, hamster anti-CD11c MAb-HL3,
control MAb-G235-2356 against the hapten trinitrophenol,
and mouse anti-MHC I Mab-KH117 to H-2Dq/H2Lq
haplotypes were also purchased (PharMingen Int., San
Diego, CA). Polyclonal goat anti-HCoV-229E was pro-
duced from NP40-disrupted, UV-inactivated HCoV-229E
purified by sucrose density gradient centrifugation in
collaboration with Lawrence Sturman (Wadsworth Center,
New York State Health Department, Albany, NY). FACS
and IFA procedures were done as previously described
(Wentworth and Holmes, 2001).
RT-PCR and nested PCR
An anchored and tailed oligo-dT (oligo-dT/Xho1) primer
was used for reverse transcription (RT) of 5–10 Ag of total
cellular RNA with Superscript reverse transcriptase (Invi-
trogen) in a 20-Al reaction. 2-Al of cDNA was amplified by
PCR with an hAPN-specific forward primer (APN-2880)
and oligo-dT/Xho1 reverse primer which maintains specif-
icity for polyadenylated RNA. Temperature cycling param-
eters were 30 cycles of 94 8C for 30 s, 57 8C for 45 s, and 72
8C for 1 min. This yielded a 712-base pair (bp) product from
RNA produced by the transgene construct and a 614-bp
from RNA of the natural human transcript expressed in
MRC5 cells. To control for RNA integrity and cDNA
production, mouse glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) was also amplified from 2 Al of the same
cDNA using a GAPDH-specific forward primer (G3P-279)
and the oligo-dT/Xho1 reverse primer. An aliquot (2 Al)
from the hAPN RT-PCR reaction was used as template in
another PCR reaction with a hemi-nested set of primers that
amplify a 439-bp fragment. The forward primer was specific
to hAPN (DT31) and the same reverse primer used in the
first round amplification (oligodT/Xho1) was used to
maintain the specificity for mRNA. The reaction conditions
were the same as used for the first round of RT-PCR. A 20-
Al aliquot of this hemi-nested (HN) reaction was electro-
phoresed through an agarose gel with molecular weightmarkers (100-bp DNA ladder, Invitrogen) and visualized by
ethidium bromide staining.
A very sensitive RT-PCR-based procedure to detect
HCoV-229E genomic viral RNA and subgenomic RNA
that is indicative of virus entry and initiation of RNA
transcription in the tissues of inoculated mice was devel-
oped. The reaction conditions and oligonucleotide primers
will be provided upon request (Table 1).
Tissue sections
Wild type and hAPN-transgenic mice were euthanized as
approved by the University of Colorado Animal Care and
Use Committee. Tissues were excised, placed in Tissue-Tek
O.C.T compound (VWR Int. Aurora, CO), and frozen in
liquid nitrogen-cooled isopentane. Frozen tissues were
sectioned 10-Am-thick with a microtome/cryostat (Leica
CM 1850-3-1 Chantilly, VA) using Accu-edge low profile
blades (VWR Int.). Initially, the sections were incubated in
C-buffer [PBS containing 1% FBS (GIBCO BRL)] for 20
min. Human APN was detected in frozen sections with 5 ng
of a biotinylated mouse anti-hAPN MAb-DW1. Mouse
APN was detected with a rat MAb (R3-242, PharMingen
Int., San Diego, CA) against mAPN. Sections were
incubated with the primary antibodies for 1 h in a
humidified chamber, then rinsed 4 times for 5 min in C-
buffer. Anti-mAPN-treated sections were incubated for an
additional hour with 5 ng of biotinylated rabbit anti-rat
antibody (H0408, Vector Laboratories) and rinsed 4 times
for 5 min in C-buffer. To reveal antibody binding, the
sections were incubated in Vectastain ABC-AP (Vector
Laboratories, Burlingame, CA) for 30 min and rinsed 3
times for 5 min with C-buffer. Next, the sections were
incubated in Vector Red substrate (Vector Laboratories) for
1–3 min, rinsed in C-buffer, stained with Hematoxylin QS
(Vector Laboratories) for 30 s, and rinsed with tap water.
Sections were dehydrated by serial washes in 75%, 95%,
and 100% ethanol and incubated for 2 min in xylene prior to
mounting with Vectamount (Vector Laboratories).Acknowledgments
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